The Department of Veterans Affairs (VA) is seeking qualified sources to provide F18 PSMA Pylarify, a radiopharmaceutical used for positron emission tomography (PET) imaging of prostate cancer, to the Baltimore VA Medical Center. The procurement aims to identify contractors capable of manufacturing, preparing, and transporting this specialized radiopharmaceutical in compliance with stringent regulatory standards, including USNRC, DOT, and FDA guidelines. Pylarify is critical for diagnosing prostate cancer by identifying PSMA-positive lesions, thus playing a vital role in patient care. Interested parties must submit their responses, including company information and qualifications, by December 17, 2025, at 10:00 AM EST, to Contract Specialist Michael Jones at michael.jones16@va.gov.